Opendata, web and dolomites

SilkByPass

Develop simple tissue regeneration technologies for the benefits of humanity by leveraging the biomimetic properties and the mechanical advantages of a new silk manufacturing nanotechnology.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SilkByPass project word cloud

Explore the words cloud of the SilkByPass project. It provides you a very rough idea of what is the project "SilkByPass" about.

readiness    human    platform    small    dangerous    patient    performed    synthetic    calibre    artery    few    silkbypass    capitalists    mammary    man    vein    peripheral    advantages    licensing    requiring    body    agreements    stimulates    carotids    designed    always    reimbursement    regeneration    opinion    tissue    clinicians    drawbacks    company    series    technological    previously    negotiations    commercial    standard    failed    bypass    market    mainly    vessels    urgent    cheaper    trials    risk    annually    made    saphenous    grafts    feasibility    560k    de    bloodstream    solutions    drugs    graft    sustainability    85bn    mechanical    companies    autograft    faster    procedure    plan    leaders    fail    golden    viability    device    medical    coronary    silk    cabg    biomimetic    risks    9bn    strengthen    venture    engineering    leveraging    surgery    oecd    natural    poor    revolutionize    biomaterials    global    surgeries    investment    umbilical    undertaken    restoring    rejection    veins    first    clinical    blood    degradation    innovative    autografts    countries    nanotechnology   

Project "SilkByPass" data sheet

The following table provides information about the project.

Coordinator
SILK BIOMATERIALS SRL 

Organization address
address: VIA CAVOUR 2
city: LOMAZZO CO
postcode: 22074
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.silkbiomaterials.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2015-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SILK BIOMATERIALS SRL IT (LOMAZZO CO) coordinator 50˙000.00

Map

 Project objective

Silk Biomaterials is a nanotechnology platform company. Its goal is to revolutionize the €85bn global tissue engineering market by leveraging the biomimetic properties and the mechanical advantages of silk. SilkByPass, a device designed for the regeneration of small blood vessels, will be the first product developed by Silk Biomaterials. About 560k/year coronary artery bypass graft surgeries (CABG) are performed in OECD countries. The current golden standard for CABG is autograft (mainly saphenous vein, umbilical vein and mammary artery) and very often more than one graft is required for each procedure. However, autografts are not always available and present several drawbacks: so, there is a global urgent need for man-made grafts. Very few synthetic grafts are on the market and, due to their very poor results, they are used only when autografts previously failed. There is also a need for man-made solutions for peripheral blood vessels, like saphenous veins and carotids. For those vessels there are no autografts available and small calibre synthetic grafts fail in restoring the bloodstream. Our innovative nanotechnology stimulates faster natural human tissue regeneration, with no rejection risks or use of drugs. In addition to that, it is cheaper than other synthetic grafts, allows for easy surgery and doesn’t produce any dangerous degradation product in the patient’s body. Key opinion leaders, clinicians, venture capitalists and medical device companies have already recognized its commercial potential, which is estimated to be around €3.9bn annually in OECD countries. The feasibility assessment to be undertaken in Phase 1 will help Silk Biomaterials further de-risk its technological/commercial viability and plan for a series of activities requiring Phase 2 funding (i.e.: clinical trials, reimbursement negotiations, distribution and licensing agreements, etc.) that will improve the investment readiness of our company and strengthen its long term sustainability.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SILKBYPASS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SILKBYPASS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

NANOHIGH (2015)

High volume production facility for high accuracy nanocapsules

Read More  

InLineNano (2015)

In-Line Areal Surface Measurement for Micro and Nano Production

Read More